AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03005054 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: StrataGraft Skin Tissue
Description: StrataGraft® skin tissue is provided as a suturable rectangular piece of stratified epithelial tissue composed of a living dermal matrix containing dermal fibroblasts overlaid with human epidermal keratinocytes (NIKS®).
Study NCT03005054 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autograft
Description: The current standard of care procedure for the treatment of severe complex skin defects. The procedure involves the removal of a sheet of healthy skin from an uninjured site on the patient and using it to cover the original wound.
Study NCT03011658 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: venepuncture
Description: for both the groups, HADS questionnaire will be administered to assess the levels of anxiety and depression. The placebo group ( group A) will not be having subjects suffering from oral lichen planus
Study NCT03011658 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: venepuncture
Description: for both the groups, HADS questionnaire will be administered to assess the levels of anxiety and depression. The placebo group ( group A) will not be having subjects suffering from oral lichen planus
Study NCT00983983 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oxepa
Description: Oxepa: Tube feed containing 1.5 calories/ml of which 55% calories are from fat, including eicosapentaenoic acid and gamma-linolenic acid. Subjects will receive 1.25 times their daily caloric requirements based on their measured resting energy expenditure. Subjects will receive 4 months of tube feeds and be followed for an additional 1 month to measure adverse events and tolerability.
Study NCT00983983 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Jevity 1.5
Description: Jevity 1.5: Tube feed containing 1.5 calories/ml of which 29.4% are from fat. Subjects will receive 1.25 times their daily caloric requirements based on their measured resting energy expenditure. Subjects will receive 4 months of tube feeds and be followed for an additional 1 month to measure adverse events and tolerability.
Study NCT00983983 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Jevity 1.0
Description: Jevity 1.0: Control tube feed. Subjects will receive 1.0 times their daily caloric requirements based on their measured resting energy expenditure. Subjects will receive 4 months of tube feeds and be followed for an additional 1 month to measure adverse events and tolerability.
Study NCT03995264 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound -guided cannulation
Description: radial artery cannulation using the ultrasound
Study NCT03995264 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Palpation -guided cannulation
Description: radial artery cannulation using the palpation
Study NCT04270929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: During Cycles 1 and 2, standard of care systemic FOLFIRI will be delivered on Days 2-4 following oxaliplatin PEDD-PRVI.
Study NCT04270929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Description: During Cycles 3-6, standard of care systemic FOLFIRINOX will be administered on Days 1-3.
Study NCT04270929 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TriSalus Infusion System
Description: The TriSalus Infusion System administers therapeutics using PEDD technology.
Study NCT02257190 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: One hour of rest.
Study NCT02257190 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IW3
Description: A one hour exercise bout with repeated cycles of 3 min of fast and 3 min of slow walking
Study NCT02257190 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IW1
Description: A one hour exercise bout with repeated cycles of 1 min of fast and 1 min of slow walking
Study NCT01236430 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe
Description: Ezetimibe 10mg tablet given orally after an overnight fast (at least 10 hours).
Study NCT01236430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe/atorvastatin 10mg/10mg FDC
Description: Ezetimibe/atorvastatin 10mg/10mg FDC tablet given orally after an overnight fast (at least 10 hours).
Study NCT01236430 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 10mg
Description: Atorvastatin 10mg given orally after an overnight fast (at least 10 hours).
Study NCT01236430 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 80mg
Description: Atorvastatin 80mg tablet given orally after an overnight fast (at least 10 hours).
Study NCT01236430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe/atorvastatin 10mg/80mg FDC
Description: Ezetimibe/atorvastatin 10mg/80mg FDC tablet given orally after an overnight fast (at least 10 hours).
Study NCT04219150 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical cardiometry
Description: Four sensors of EC will be applied : first approximately 5 cm above the base of the neck, second on the base of neck, third on the lower thorax at the level of the xiphoid and the fourth one on the lower thorax approximately 5 cm below the 3rd electrode at the level of anterior axillary line. The EC monitor (Electrical Cardiometry monitor, ICON Cardiotronics, Inc., La Jolla, CA 92307; Osyka Medical GmbH, Berlin, and Germany, model C3, serial number 1725303) will be connected to the sensor cable and the patient data will be fed. Corrected flow time (FTC) and stroke volume (SV) will be measured continuously in less than 30 seconds after placing the sensors and inputting the height and weight.
Study NCT04219150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluid and Catheter Treatment Trial FACTT Lite
Description: The FACTT Lite provided three possible instructions determined by the CVP and urine output: furosemide administration, fluid bolus, or no intervention. FACTT Lite contained instructions to withhold furosemide until the patient achieved a mean arterial pressure greater than 60 mmHg off of vasopressors for at least 12 h.
Study NCT02630238 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Branched-Chain Amino Acid Supplementation
Description: All participants will partake in the same diet \& exercise regime but this group will also be placed on a BCAA intake level of 0.342g/kg of BCAA per day
Study NCT02630238 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All participants will partake in the same diet \& exercise regime but this group will receive an isocaloric placebo in form of carbohydrate solution
Study NCT02630238 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise will take place in a class based, circuit training setting run by a certified personal trainer composed of both aerobic and lifting exercises
Study NCT02630238 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Exercise
Description: Exercise will take place in a class based, circuit training setting run by a certified personal trainer composed of both aerobic and lifting exercises
Study NCT02630238 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: Each participants will be placed on a daily energy deficit of 500 calories for the 8 week study period.
Study NCT02630238 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Diet
Description: Each participants will be placed on a daily energy deficit of 500 calories for the 8 week study period.
Study NCT00915200 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: 600 mg orally twice daily for three months
Study NCT00915200 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: silibin
Description: 480 mg orally twice daily for three months
Study NCT00915200 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: high-dose silibin
Description: 960 mg orally twice daily for three months
Study NCT00915200 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: N-acetylcysteine placebo
Description: excipient orally twice daily for three months
Study NCT04340141 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin Calcium
Description: Given IV
Study NCT04340141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV
Study NCT04340141 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: Given IV
Study NCT04340141 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection
Description: Undergo surgical resection
Study NCT04340141 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Resection
Description: Undergo surgical resection
Study NCT04340141 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04340141 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT00915200 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine placebo
Description: excipient orally twice daily for three months
Study NCT00915200 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: silibin placebo
Description: excipient orally twice daily for three months
Study NCT00915200 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: silibin placebo
Description: excipient orally twice daily for three months
Study NCT00533078 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: omegaven
Description: Trial participants are prescribed TPN by the attending physician as soon as indicated, which will be administered via a central venous line over a time period of approximately 20 hours per day. The formulation given to all patients is Nutriflex lipid spezial®, an emulsion containing the full supply of carbohydrates, amino acids and lipids (SO:MCT = 1:1) with a total energy content of 2215 kcal in a 1875 ml volume, see Investigator's Brochure. In addition, they receive daily infusional Omegaven® 100 ml over 4 hours, which equal FO 10 g/d or omega-3 PUFA 3-6 g/d.
Study NCT01851850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opicapone
Description: 25mg or 50mg once per day
Study NCT02642978 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RSRCLM
Description: The Da Vinci Surgical System may help to overcome some of the difficulties of laparoscopy for complicated abdominal surgery. The aim of this study was to present an innovative technique that is robot-assisted, simultaneous radical resection of both colorectal cancer and liver metastasis (RSRCLM).
Study NCT02642978 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open
Description: Traditional open simultaneous radical resection of both colorectal cancer and liver metastasis
Study NCT02872454 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Messaging
Description: Each week, enrolled participants will receive daily text messages from one of three randomly assigned psychotherapeutic modalities-cognitive restructuring, behavioral activation, and techniques based on Acceptance and Commitment Therapy (ACT)-for a total of 12 weeks. The messages were developed, reviewed, and refined by a multidisciplinary team of experienced therapists, including social workers, psychologists, and psychiatrists.
Study NCT02161562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omalizumab
Description: 150mg omalizumab via sub-cutaneous injection once every 4 weeks
Study NCT02161562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omalizumab
Description: 300mg omalizumab via sub-cutaneous injection once every 4 weeks
Study NCT01394705 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BodyMedia
Description: Accelerometer
Study NCT02750787 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional Study Product
Description: Two 220 ml servings per day
Study NCT02995304 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine premedication
Description: 30 children will 0.1 mg/kg morphine as a premedication 20 to 30 min before surgical incision.
Study NCT02995304 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam premedication
Description: All children who will receive 0.025 mg/kg midazolam IV as a premedication 20 to 30 min before surgical incision.
Study NCT02995304 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline premedication (placebo)
Description: 30 children in midazolam only group will receive saline after midazolam
Study NCT03344666 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Step 1 Treatment BI+HC
Description: Participants in the Brief intervention + Health Coach (BI+HC) will receive a BI in the ED, followed by weekly sessions with the Health Coach for 4 weeks, which will occur by phone or in person. During sessions, the HC will review the prior week's progress, and discuss goals and plans for the following week.
Study NCT03344666 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Step 1 Treatment BI+TM
Description: Participants in the Brief intervention + Text messages (BI+TM) will receive a BI in the ED, followed by daily TMs for 4 weeks. TM's are tailored based on weekly surveys and focus on motives for alcohol and violence and strategies to reduce involvement.
Study NCT03344666 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Step 2 Treatment Responders
Description: Participants in the BI+HC assigned to stay the course (e.g., continue to receive the HC) will have 4 more weekly sessions with the HC.~Participants in the BI+TM assigned to stay the course (e.g., continue to receive the TM) will receive 4 more weeks of TM.~Participants in the BI+HC or BI+TM assigned to stepped down control will receive a brochure containing community resources.
Study NCT03344666 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Step 2 Treatment Non-Responders
Description: Participants in the BI+HC assigned to be stepped up will receive HC+, which will consist of weekly sessions as well as on daily TMs from the HC.~Participants in the BI+HC assigned to stay the course (e.g., continue to receive the HC) will have 4 more weekly sessions with the HC.~Participants in the BI+TM assigned to be stepped up will receive the HC, which consists of 4 weekly sessions with the HC.~Participants in the BI+TM assigned to stay the course (e.g., continue to receive the TM) will receive 4 more weeks of TM.
Study NCT03616431 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pancreo-KIT breath test
Description: Pancreo-Kit (Isomed Pharma, Madrid, Spain) is a breath test devised to measure Pancreatic Enzyme Insufficiency. It is a non-invasive method to obtain information about the digestion of consumed lipids; this in turn is informative about the exocrine enzyme activity of the pancreas (specifically pancreatic lipase). This kit is manufactured to EC directive 98/79/EEC and carries the CE mark.~The test is based on measurement of 13C which is a stable naturally occurring environmental isotope of carbon with a nucleus containing 6 protons and 7 neutrons (note, it is not radioactive).
Study NCT04845412 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Hearing screening tests
Description: Our study was conducted in accordance with the National Hearing Screening Test Protocol. The newborns had transient evoked otoacoustic emissions (TEOAE) with click stimulus as a hearing screening test in the first three days after birth, using Otometrics Madsen Accuscreen S/N: 36484 (USA) device.
Study NCT00577993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine
Description: Group 1= 25 mg/m\^2 IV over 15 min. Days 2 through 4 for 8 Cycles; Group 2 = 25 mg/m\^2 IV over 15 min. Days 1 through 3 for 8 Cycles.
Study NCT00577993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Novantrone
Description: Group 1 = 10 mg/m\^2 IV over 15 min. Day 2 for 8 Cycles; Group 2 = 10 mg/m\^2 IV over 15 min. Day 1 for 8 Cycles; Group 3 = 10 mg/m\^2 IV over 15 min. Day 2 of 3rd Sequence.
Study NCT00577993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Decadron
Description: Group 1 = 20 mg IV over 15 min. Days 1 through 5 for 8 Cycles, then Days 1 through 3 Every Month for 1 Year; Group 2 = 20 mg IV over 15 min. Days 1 through 5 for 8 Cycles, then Days 1 through 3 Every Month for 1 Year; Group 3 = 40 mg PO Days 1 through 4 of 1st Sequence; After Completion of 3 Sequences, Days 1 through 3 Every Month for 1 Year.
Study NCT00577993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Group 1 = 375 mg/m\^2 IV Days 1 through 8 of Course 1, then Day 1 Only of Cycles 2 through 5; Group 2 = 4 Months after IFN Starts, 375 mg/m\^2 IV Once Per Month for 6 Months; Group 3 = 375 mg/m\^2 IV Days 1 through 8 of 1st Sequence; 375 mg/m\^2 IV Days 1 through 8 of 3rd Sequence.
Study NCT00577993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon
Description: Group 1 = After Completion of Fludarabine, Novantrone, \& Rituximab, IFN 3 mcg/ml/m\^2 SQ Days 1 through 14 Each Month for 1 year; Group 2 = After Completion of Fludarabine \& Novantrone, IFN 3 mcg/ml/m\^2 SQ Days 1 through 14 Each Month for 1 year; Group 3 = After Completion of 3 Sequences, IFN 3 mcg/ml/m\^2 SQ Days 1 through 14 Each Month for 1 year.
Study NCT00577993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: 25 mg/m\^2 IV Days 2 \& 3 of 1st Sequence.
Study NCT00577993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: .7 mg/m\^2 IV Days 2 \& 3 of 1st Sequence; 1.4 mg/m\^2 IV Day 2 of 3rd Sequence.
Study NCT00577993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bleomycin
Description: 5 unit/m\^2 IV Days 2 \& 3 of 1st Sequence.
Study NCT00577993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 750 mg/m\^2 IV Day 2 of 1st Sequence.
Study NCT00577993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: 40 mg/m\^2 IV Days 1 through 4 of 2nd Sequence.
Study NCT00577993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 25 mg/m\^2 IV Days 1 through 4 of 2nd Sequence
Study NCT00577993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ara-C
Description: 1.5 gm/m\^2 IV Day 5 of 2nd Sequence.
Study NCT00577993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methyl-Prednisolone
Description: 500 mg IV Days 1 through 5 of 2nd Sequence.
Study NCT00577993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Procarbazine
Description: 100 mg/m\^2 PO Days 2 through 11 of 3rd Sequence.
Study NCT00577993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: 100 mg PO Days 1 through 5 of 3rd Sequence.
Study NCT00648167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ferric citrate
Description: ferric citrate will be provided as a 375mg capsule. Dosing and frequency are dependent on patient's serum phosphorus levels. Dosing will occur over the 28-day study.
Study NCT02828410 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SBI
Description: Serum bovine immunoglobulin protein isolate 10 g twice per day
Study NCT02735629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CX1739 - 300 mg
Description: Ampakine CX1739 - 300 mg
Study NCT02735629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CX1739 - 600 mg
Description: CX1739 - 600 mg
Study NCT02735629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CX1739 - 900 mg
Description: CX1739 - 900 mg
Study NCT02735629 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to 300 mg CX1739
Study NCT02342405 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 80% oxygen
Study NCT02342405 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 30% oxygen
Study NCT01895127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eculizumab
Study NCT01895127 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Immunoglobulin
Study NCT01895127 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Plasmapheresis
Study NCT00157612 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: a clinical pathway nursing home acquired pneumonia
Description: treatment in nursing homes according to a clinical pathway, which included use of oral anti-microbials, portable chest radiographs, oxygen saturation monitoring, rehydrations and close monitoring by research nurse
Study NCT00119158 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combination of pimecrolimus and fluticasone
Description: Pimecrolimus cream twice a day and fluticasone cream once a day
Study NCT00119158 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pimecrolimus
Description: apply daily with fluticasone cream for flares
Study NCT00119158 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: pimecrolimus
Description: apply daily with fluticasone cream for flares